Stocktoria
Viridian Therapeutics, Inc.DE VRDN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-18
Viridian Therapeutics, Inc.DE statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% |
| Net margin | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% |
| FCF margin | -390.8% | -77096.0% | -58938.9% | -5340.6% | -1853.5% |
| Return on assets | -38.1% | -36.4% | -48.5% | -29.8% | -39.0% |
| Return on equity | -47.4% | -40.2% | -53.8% | -32.9% | -42.3% |
| Debt / equity | — | 0.03× | 0.05× | 0.01× | 0.00× |
| Current ratio | 12.65 | 15.43 | 18.26 | 12.93 | 14.68 |
| Revenue growth | 23359.9% | -3.8% | -82.3% | -40.2% | 182.2% |
Source: SEC EDGAR filings · CIK 0001590750 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.